Innate Pharma

IPHANasdaq France Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$162.257 M

$1.73 -3.08%

Close of 7 Aug 2026

Revenue

—

Not reported

Earnings

—

Not reported

Shares outstanding

93,719,323

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances) — ranked by market cap

All 160 →

#106Molecular PartnersMOLN$163.5M
#107Tenaya TherapeuticsTNYA$163.0M
#108Innate PharmaIPHA$162.3M
#109HumacyteHUMA$159.5M
#110Entera BioENTX$141.5M

Where these numbers come from

Share counts and financials for Innate Pharma are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.